Most drug or device launches today require a health economic valuation often in the form of a Health Technology Assessment (HTA) to satisfy payers that the new ‘technology’ is advantageous for the...
Black Swan Analysis Blog
The need for accurate epidemiology data to drive a higher success rate with Health Technology Assessments
Portfolio Optimisation: Can you really compare Apples to Oranges?
When someone uses the expression "you're comparing apples to oranges" they're really saying "Why are you trying to compare those things? You can't compare apples to oranges; they're just not the...
Forecasting In Forgotten Markets
Two recent healthcare events supported by the One Nucleus biotech network, has nicely highlighted some of the challenges facing healthcare companies and investors that are looking to bring...
Forecasting in Dynamic Oncology Markets
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month. Firstly how exciting the market is right now, with many productive collaborations...
Shire bets big on rare diseases
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical...
Understanding the ‘big picture’
In this article, Nic Talbot-Watt, Director of Analysis and Forecasting at Black Swan Analysis, highlights the advantage of having a robust commercial understanding of their healthcare innovation...
Can rare diseases be a viable option for the pharma industry?
In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US...
Defining patient populations is a key trend shaping the pharma industry
Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the...
Enablers of drug innovation could lie in the numbers
Christopher Ehinger of Black Swan Analysis addresses the problem of clinical-trial recruitment as a barrier to new drug development and offers a new way of looking at the problem.
Forecasting for licensed compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharma forecasting.